Dr. Reddy'S Labs Peer Comparison

NSE: DRREDDY | BSE: 500124

₹1,178.00

₹1.00 (0.08%)

As on 28-Aug-2026IST

Market cap

₹98,309 Cr

Revenue (TTM)

₹33,228 Cr

P/E Ratio

30.5

P/B Ratio

2.6

Div. Yield

0.7 %

Edit

	Dr. Reddy'S Labs	Zydus Lifesciences	Lupin	Mankind Pharma	Aurobindo Pharma
Market cap (₹ Cr)	98,309	1,18,404	99,455	98,599	94,937
Revenue (₹ Cr)	33,228	28,592	29,967	14,738	34,935
Net Profit (₹ Cr)	3,169.30	4,492.20	5,551.01	2,055.11	3,712.74
Net Margin (%)	9.15	14.92	18.23	13.64	10.42
RoE (%)	8.72	18.78	28.32	13.60	10.38
Price to Earnings	30.51	26.24	17.99	48.27	25.57
Price-To-Book	2.58	4.39	4.18	5.86	2.44

Income Statement (₹ Cr)

	Dr. Reddy'S Labs	Zydus Lifesciences	Lupin	Mankind Pharma	Aurobindo Pharma
Operating Revenue	33,227.90	28,591.70	29,966.58	14,737.88	34,935.29
Total Income	34,650.70	30,111.40	30,442.31	15,061.79	35,624.79
Total Expenditure	28,088.10	21,334.70	20,428.27	10,911.05	27,850.01
EBITDA	5,139.80	7,257.00	9,538.31	3,826.83	7,085.28
Depreciation	2,119.30	1,724.60	1,529.37	893.20	1,859.31
EBIT	3,020.50	5,532.40	8,008.94	2,933.63	5,225.97
Interest	416.30	510.20	452.37	578.61	387.88
Other Income	1,422.80	1,519.70	475.73	323.91	689.50
Exceptional Items	0.00	-534.80	-557.91	-129.75	-105.51
Profit before Tax	4,027.00	6,007.10	7,474.39	2,549.18	5,422.08
Provision for Tax	857.70	1,514.90	1,923.38	494.07	1,709.34
Profit after Tax	3,169.30	4,492.20	5,551.01	2,055.11	3,712.74

	Dr. Reddy'S Labs	Zydus Lifesciences	Lupin	Mankind Pharma	Aurobindo Pharma
Shareholder's Funds	37,891.50	27,111.40	22,448.27	16,300.34	37,890.97
Minority Interest	38.90	-79.70	-22.18	-24.90	1.76
Non-Current Liabilities	3,145.10	7,112.50	3,200.22	5,011.23	2,580.33
Current Liabilities	16,747.40	15,711.90	12,651.24	6,507.25	18,039.01
Total Liabilities	56,576.70	50,672.60	38,146.06	27,754.83	58,196.15

	Dr. Reddy'S Labs	Zydus Lifesciences	Lupin	Mankind Pharma	Aurobindo Pharma
Non-Current Assets	27,204.00	31,677.20	11,888.82	20,274.65	24,040.45
Current Assets	30,179.30	19,906.10	24,027.38	6,954.20	32,708.75
Total Assets	56,576.70	50,672.60	38,146.06	27,754.83	58,196.15
Total Debt*	7,734.10	11,769.50	5,910.20	6,021.78	7,676.20
Net Current Assets	13,431.90	4,194.20	11,376.14	446.95	14,669.74
Contingent Liabilities	336.14	989.90	1,094.02	924.77	1,358.37

	Dr. Reddy'S Labs	Zydus Lifesciences	Lupin	Mankind Pharma	Aurobindo Pharma
Cash From Operating Activities	5,673.70	2,116.60	7,334.50	3,121.29	5,526.37
Cash Flow from Investing Activities	-6,549.30	-8,296.10	-3,864.59	-196.42	-3,458.61
Cash from Financing Activities	829.00	5,806.90	-845.87	-2,952.69	-1,269.15
Net Cash Inflow / Outflow	-46.60	-372.60	2,624.04	-27.82	798.61

	Dr. Reddy'S Labs	Zydus Lifesciences	Lupin	Mankind Pharma	Aurobindo Pharma
ROCE (%)	13.75	21.39	28.86	13.24	12.76
ROE (%)	8.72	18.78	28.32	13.60	10.38
ROA (%)	5.89	10.03	16.43	7.36	6.86
EBIT Margin (%)	9.09	19.35	26.73	19.91	14.96
Net Margin (%)	9.15	14.92	18.23	13.64	10.42
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Dr. Reddy'S Labs	Zydus Lifesciences	Lupin	Mankind Pharma	Aurobindo Pharma
Revenue Growth (%)	-0.87	21.11	28.19	14.16	9.09
EBIT Growth (%)	-55.06	-8.99	77.03	19.45	6.91
Net Profit Growth (%)	-44.66	-3.14	49.13	8.09	8.63
EPS Growth (%)	-43.29	4.31	60.86	12.27	11.88
Book Value Growth (%)	12.99	13.19	30.75	13.74	16.04

	Dr. Reddy'S Labs	Zydus Lifesciences	Lupin	Mankind Pharma	Aurobindo Pharma
Price / Earnings	30.51	24.23	16.68	45.88	25.26
Price / Book Value	2.58	4.39	4.18	5.86	2.44
Dividend Yield (%)	0.68	0.08	0.83	0.04	0.24
EV/EBITDA	19.27	16.95	10.08	26.81	12.98
Market Cap (₹ Cr)	1,04,763.81	87,643.18	1,05,737.27	82,801.75	75,689.14

	Dr. Reddy'S Labs	Zydus Lifesciences	Lupin	Mankind Pharma	Aurobindo Pharma
Debt to Equity	0.00	0.12	0.07	0.17	0.02
Short term debt to equity ratio	0.16	0.16	0.18	0.04	0.16
Current Ratio	1.80	1.27	1.90	1.07	1.81
Quick Ratio	1.35	0.91	1.42	0.74	1.15
Interest Coverage	10.67	12.77	17.52	5.41	14.98

	Dr. Reddy'S Labs	Zydus Lifesciences	Lupin	Mankind Pharma	Aurobindo Pharma
Debtors to sales (%)	30.47	18.94	22.04	11.74	20.31
Asset Turnover	0.62	0.64	0.89	0.53	0.65
Receivable days	103.79	33.55	51.23	39.93	33.71
Inventory Days	79.94	33.80	48.93	51.78	59.32
Payable days	84.78	149.82	205.75	111.46	148.20
Cash Conversion Cycle	98.95	-82.46	-105.59	-19.75	-55.17

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.